BioSpace News Archive

Genetown

Sanguine Biosciences Announces $10 Million Credit Financing from Catalio Capital Management to Fund Continued Growth

Sanguine Biosciences today announced that it secured $10 million in credit financing from Catalio Capital Management, a leading multi-strategy healthcare and life science investment firm.

October 31, 2023
·
3 min read
BioInvent presents preclinical data at SITC providing clear evidence of the potential of anti-TNFR2 antibody BI-1910

BioInvent will present preclinical data on its anti-tumor necrosis factor receptor 2 (TNFR2) agonistic antibody BI-1910 at the Society of Immunotherapy for Cancer (SITC) 38th Annual Meeting in San Diego, California.

October 31, 2023
·
3 min read
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, is reporting the outcome of a protocol-defined interim analysis

October 31, 2023
·
9 min read
Business

Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC

Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present new findings at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting regarding its first-of-its-kind collaboration with Moderna.

October 31, 2023
·
6 min read
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, to present outcome data from Cohort 1 of its pivotal SPEARHEAD-1 trial at the Connective Tissue Oncology Society

October 31, 2023
·
7 min read
Business

Third Harmonic Bio Announces Leadership Changes

Third Harmonic Bio, Inc. today announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific Officer to Scientific Advisor, effective November 1, 2023.

October 31, 2023
·
3 min read
Business

Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission

Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, after the close of the U.S. financial markets.

October 31, 2023
·
4 min read
Drug Development

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Apollomics Inc. today announced the addition of two new cohorts in its ongoing global multi-cohort Phase 2 SPARTA study (NCT03175224), which is evaluating vebreltinib (APL-101) in patients with non-small cell lung cancer (NSCLC) and other solid tumors.

October 31, 2023
·
6 min read
Biotech Beach

Simulations Plus to Host Investor Day on Tuesday, November 14th

Simulations Plus, Inc. announced that it will hold a virtual Investor Day on Tuesday, November 14, 2023, beginning at 1:00 p.m. Eastern time.

October 31, 2023
·
1 min read
Pharm Country

U.S. FDA AWARDS BOTH RARE PEDIATRIC DISEASE AND ORPHAN DRUG DESIGNATIONS TO HG204, A CRISPR RNA-EDITING THERAPY, FOR THE TREATMENT OF MECP2 DUPLICATION SYNDROME

HuidaGene Therapeutics today announced the U.S. Food and Drug Administration (FDA) had granted both the Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to HG204 for the treatment of MECP2 duplication syndrome (MDS), a rare and fatal childhood neurodevelopmental disorder for which there is no treatment.

October 31, 2023
·
5 min read